Hansa Biopharma — December 2024
-
Citat fra pressemed.: Lund, Sverige, 17. december 2024. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), annoncerede i dag positive fuldstændige resultater fra 15-HMedIdeS-09 enkeltarms fase 2-studiet af imlifidase, et første i klassen IgG-spaltningsenzym, i Guillain-Barré syndrom (GBS) og en indirekte behandlingssammenligning af 15-HMedIdeS-09 studiedata til International Guillain-Barré Syndrome Outcome Study (IGOS), et verdensomspændende prospektivt studie fra Inflammatory Neuropathy Consort
-
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
-
Shorting Hansa Biopharma https://shortnordic.com/details_company.php?company=hansa biopharma&land=sweden
-
Tilsyneladende en ny Hansa Biopharma hjemmeside:
Hansa Biopharma - Home
We develop lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.
(www.hansabiopharma.com)
-
FYI Hansa Biopharma
shorting: https://shortnordic.com/history_company.php?selskapsnavn=HANSA BIOPHARMA&land=sweden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind